Dr Eva Littringer
Co-Founder and Chief Executive Officer

About

Eva Littringer, PhD, is Co-Founder and Chief Executive Officer of Oncofuse, where she leads the development of integrated, next-generation packaging solutions designed to improve the safety, efficiency, and scalability of RLT delivery. She holds a Master’s in Pharmacy and a Master’s and PhD in Pharmaceutical Engineering. With over 15 years of experience across the pharmaceutical value chain, including senior R&D roles at Sandoz and Novartis, expertise in pharmaceutical excipients, prior work as an expert at the Austrian Medicines Agency and as an expert member of the European Directorate for the Quality of Medicines & Healthcare, she brings deep scientific, technical and commercial expertise to advancing safer, scalable radiopharmaceutical workflows.

She is the inventor on multiple filed patents, including a granted patent, and has received several innovation awards, including recognition at the European Forum Alpbach, the Best of Biotech Award and the Drug Delivery to the Lungs Pat Burnell Young Investigator Award.

Contributions

EARLY INSIGHT

SCALING RADIOLIGAND THERAPY: WHY PACKAGING AND DELIVERY SYSTEMS MUST EVOLVE

Dr Eva Littringer and Dr Roland Starlinger discuss the exciting new frontier of radioligand therapy and the imminent bottleneck presented by current delivery methods running into strict limits on handling radioactive materials. They go on to introduce the Oncofuse prefilled-syringe-based system as a novel approach to containment and handling of these therapies, enabling radioligand therapy to expand beyond niche specialist clinics and hospitals.